Scholarlink

Objective <p>This study aimed to explore the clinical significance of the cytokinesis-associated gene <i>NUF2</i> and the immune-related gene <i>CD52</i> in non-small cell lung cancer (NSCLC), with a focus on their association with platinum-based chemoresistance and patient prognosis.</p> Methods <p>Cancer and matched adjacent non-tumorous tissues were obtained from 72 NSCLC patients who underwent surgical resection. Immunohistochemical (IHC) staining was performed to assess the expression of <i>NUF2</i> and <i>CD52</i>. Patients were stratified based on combined staining intensity and extent scores. All patients received gemcitabine plus cisplatin chemotherapy. Associations between gene expression and chemotherapy response, clinicopathological features, and overall survival were evaluated. Kaplan–Meier survival analysis and Cox regression modeling were used to identify independent prognostic factors.</p> Results <p><i>NUF2</i> and <i>CD52</i> showed significantly higher expression in NSCLC tissues compared to adjacent controls (66.67% and 62.50% positivity, respectively; <i>P</i> &lt; 0.05). Positive expression of both genes was significantly associated with advanced TNM stage, poor differentiation, lymph node metastasis, pleural invasion, and vascular thrombus formation (<i>P</i> &lt; 0.05). Post-chemotherapy non-remission rates were significantly elevated in <i>NUF2</i>- and <i>CD52</i>-positive patients (<i>P</i> &lt; 0.05). Kaplan–Meier analysis revealed markedly reduced median survival in patients with positive <i>NUF2</i> and <i>CD52</i> expression (<i>P</i> &lt; 0.05). Multivariate Cox analysis identified platinum resistance, lymph node metastasis, pleural invasion, and positive expression of <i>NUF2</i> and <i>CD52</i> as independent predictors of poor prognosis.</p> Conclusion <p>High expression of <i>NUF2</i> and <i>CD52</i> is closely linked to platinum resistance and aggressive tumor behavior in NSCLC, and serves as an independent predictor of adverse outcomes. These markers may hold potential as prognostic indicators and therapeutic targets in chemoresistant NSCLC. These findings, while promising, are based on a single-center retrospective cohort and should be validated in larger, independent studies to confirm their clinical utility.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Elevated NUF2 and CD52 expression predict platinum-based chemoresistance and poor prognosis in non-small cell lung cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月3日

查看全文
  • Bo Liu,
  • Zhansheng Lu,
  • Jing Yao

摘要

Objective

This study aimed to explore the clinical significance of the cytokinesis-associated gene NUF2 and the immune-related gene CD52 in non-small cell lung cancer (NSCLC), with a focus on their association with platinum-based chemoresistance and patient prognosis.

Methods

Cancer and matched adjacent non-tumorous tissues were obtained from 72 NSCLC patients who underwent surgical resection. Immunohistochemical (IHC) staining was performed to assess the expression of NUF2 and CD52. Patients were stratified based on combined staining intensity and extent scores. All patients received gemcitabine plus cisplatin chemotherapy. Associations between gene expression and chemotherapy response, clinicopathological features, and overall survival were evaluated. Kaplan–Meier survival analysis and Cox regression modeling were used to identify independent prognostic factors.

Results

NUF2 and CD52 showed significantly higher expression in NSCLC tissues compared to adjacent controls (66.67% and 62.50% positivity, respectively; P < 0.05). Positive expression of both genes was significantly associated with advanced TNM stage, poor differentiation, lymph node metastasis, pleural invasion, and vascular thrombus formation (P < 0.05). Post-chemotherapy non-remission rates were significantly elevated in NUF2- and CD52-positive patients (P < 0.05). Kaplan–Meier analysis revealed markedly reduced median survival in patients with positive NUF2 and CD52 expression (P < 0.05). Multivariate Cox analysis identified platinum resistance, lymph node metastasis, pleural invasion, and positive expression of NUF2 and CD52 as independent predictors of poor prognosis.

Conclusion

High expression of NUF2 and CD52 is closely linked to platinum resistance and aggressive tumor behavior in NSCLC, and serves as an independent predictor of adverse outcomes. These markers may hold potential as prognostic indicators and therapeutic targets in chemoresistant NSCLC. These findings, while promising, are based on a single-center retrospective cohort and should be validated in larger, independent studies to confirm their clinical utility.